ArticleNeurochemical research2026
Maresin1 Improves Angiogenesis and Cognitive Function by Regulating Perivascular Macrophages in Rats with Chronic Cerebral Hypoperfusion.
Article in Neurochemical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Population aging imposes a substantial dementia burden. Chronic cerebral hypoperfusion (CCH) serves as a crucial early pathological basis for Alzheimer's disease (AD) and Vascular Dementia (VaD). Our previous studies have demonstrated that macrophage-derived docosahexaenoic acid metabolite Maresin1 can ameliorate CCH-induced cognitive impairment, though the underlying angiogenesis-related mechanisms remain to be elucidated. We developed a rat model of chronic cerebral hypoperfusion using the bilateral common carotid artery occlusion surgical approach. Cognitive improvements and angiogenic mechanisms by Maresin1 were systematically evaluated using behavioral assessments, immunofluorescence techniques, Western blotting (WB), ELISA, and cerebral blood flow measurements via laser Doppler. Our findings revealed that Maresin1 administration significantly ameliorated CCH-induced cognitive deficits, promoted hippocampal angiogenesis and enhanced cerebral perfusion. Further analysis showed significant enhancement of IGF-1/p-Akt/VEGF/eNOS signaling pathway activation by Maresin1, and the increased VEGF expression was predominantly mediated by perivascular macrophage (pvMΦ) activation. Depletion of pvMΦ using clodronate liposomes suppressed the VEGF upregulation and cognitive improvement mediated by Maresin1. Our research demonstrates that IGF-1/p-Akt/VEGF pathway activation in pvMΦ plays a crucial role in Maresin1-mediated angiogenesis in CCH rats.
Indexed as
Identifiers
42848243What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.